Related references
Note: Only part of the references are listed.Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
L. M. Flores et al.
BRITISH JOURNAL OF CANCER (2010)
Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
Lihua H. Wang et al.
CLINICAL CANCER RESEARCH (2010)
Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways
Mark R. Lackner
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
Marta Pestrin et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
Daniel S. W. Tan et al.
CANCER JOURNAL (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer
Bianca Mostert et al.
CANCER TREATMENT REVIEWS (2009)
Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer
Fumihiro Tanaka et al.
CLINICAL CANCER RESEARCH (2009)
The CTC-Chip An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients
Lecia V. Sequist et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Xiaolan Hu et al.
MOLECULAR CANCER RESEARCH (2009)
Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients
Rachel E. Payne et al.
PHARMACOGENOMICS (2009)
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device
AmirAli H. Talasaz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
Bahriye Aktas et al.
BREAST CANCER RESEARCH (2009)
Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer
Carol O'Brien et al.
CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis
G. D. Smith et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Detection of mutations in EGFR in circulating lung-cancer cells
Shyamala Maheswaran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Klaus Pantel et al.
NATURE REVIEWS CANCER (2008)
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Sunitha Nagrath et al.
NATURE (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
J Zidan et al.
BRITISH JOURNAL OF CANCER (2005)
Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization:: a technical review with interpretive guidelines
DG Hicks et al.
HUMAN PATHOLOGY (2005)
Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer
M Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E
A Jarry et al.
MOLECULAR AND CELLULAR PROBES (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Frequent EpCam protein expression in human carcinomas
PT Went et al.
HUMAN PATHOLOGY (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Natural history of early, localized prostate cancer
JE Johansson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
WJ Allard et al.
CLINICAL CANCER RESEARCH (2004)
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
C Bozzetti et al.
CANCER CYTOPATHOLOGY (2003)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
D Gancberg et al.
ANNALS OF ONCOLOGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
